The Pathogenesis of Systemic Sclerosis

被引:230
作者
Katsumoto, Tamiko R. [1 ]
Whitfield, Michael L.
Connolly, M. Kari [1 ,2 ,3 ]
机构
[1] Univ Calif San Francisco, Div Rheumatol, Dept Med, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA
[3] Dartmouth Med Sch, Dept Genet, Hanover, NH 03755 USA
来源
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 | 2011年 / 6卷
关键词
scleroderma; connective tissue disease; CREST syndrome; autoantibodies; fibrosis; microarrays; ANTIENDOTHELIAL CELL ANTIBODIES; GENOME-WIDE ASSOCIATION; PERIPHERAL-BLOOD CELLS; GROWTH-FACTOR RECEPTOR; RNA POLYMERASE-III; TGF-BETA; GENE-EXPRESSION; DERMAL FIBROBLASTS; T-CELLS; STIMULATORY AUTOANTIBODIES;
D O I
10.1146/annurev-pathol-011110-130312
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Systemic sclerosis (SSc), also known as scleroderma, is a rare connective tissue disease characterized by vascular and immune dysfunction, leading to fibrosis that can damage multiple organs. Its pathogenesis is complex and poorly understood. Two major clinical subtypes are the limited and diffuse forms. Research into SSc has been hampered by its rarity, its clinical heterogeneity, and the lack of mouse models that accurately recapitulate the disease. Clinical and basic studies have yielded some mechanistic clues regarding pathogenesis. Recent insights gained through the use of microarrays have revealed distinctive subsets of SSc within and beyond the limited and diffuse subsets. In this review, we discuss potential mechanisms underlying the vascular, autoimmune, and fibrotic points of dysregulation. Proper categorization of SSc patients for research studies by use of microarrays or other biomarkers is critical, as disease heterogeneity may explain sonic of the inconsistencies of prior studies.
引用
收藏
页码:509 / 537
页数:29
相关论文
共 148 条
[1]   Peripheral blood fibrocytes: Differentiation pathway and migration to wound sites [J].
Abe, R ;
Donnelly, SC ;
Peng, T ;
Bucala, R ;
Metz, CN .
JOURNAL OF IMMUNOLOGY, 2001, 166 (12) :7556-7562
[2]   New developments in fibroblast and myofibroblast biology: Implications for fibrosis and scleroderma [J].
Abraham D.J. ;
Eckes B. ;
Rajkumar V. ;
Krieg T. .
Current Rheumatology Reports, 2007, 9 (2) :136-143
[3]   Scleroderma: from cell and molecular mechanisms to disease models [J].
Abraham, DJ ;
Varga, J .
TRENDS IN IMMUNOLOGY, 2005, 26 (11) :587-595
[4]   The genetics of scleroderma (systemic sclerosis) [J].
Agarwal, Sandeep K. ;
Reveille, John D. .
CURRENT OPINION IN RHEUMATOLOGY, 2010, 22 (02) :133-138
[5]   Treatment With Imatinib Prevents Fibrosis in Different Preclinical Models of Systemic Sclerosis and Induces Regression of Established Fibrosis [J].
Akhmetshina, Alfiva ;
Venalis, Paulius ;
Dees, Clara ;
Busch, Nicole ;
Zwerina, Jochen ;
Schett, Georg ;
Distler, Oliver ;
Distler, Joerg H. W. .
ARTHRITIS AND RHEUMATISM, 2009, 60 (01) :219-224
[6]   Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13 [J].
Aliprantis, Antonios O. ;
Wang, Jingsong ;
Fathman, John W. ;
Lemaire, Raphael ;
Dorfman, David M. ;
Lafyatis, Robert ;
Glimcher, Laurie H. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (08) :2827-2830
[7]   CXCL10 (α) and CCL2 (β) chemokines in systemic sclerosis -: a longitudinal study [J].
Antonelli, A. ;
Ferri, C. ;
Fallahi, P. ;
Ferrari, S. M. ;
Giuggioli, D. ;
Colaci, M. ;
Manfredi, A. ;
Frascerra, S. ;
Franzoni, F. ;
Galetta, F. ;
Ferrannini, E. .
RHEUMATOLOGY, 2008, 47 (01) :45-49
[8]   Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis [J].
Arnett, FC ;
Targoff, IN ;
Mimori, T ;
Goldstein, R ;
Warner, NB ;
Reveille, JD .
ARTHRITIS AND RHEUMATISM, 1996, 39 (09) :1507-1518
[9]  
Arnett FC, 2001, ARTHRITIS RHEUM-US, V44, P1359, DOI 10.1002/1529-0131(200106)44:6<1359::AID-ART228>3.0.CO
[10]  
2-S